Measuring Outcomes

Christy Zigler, PhD, MSEd Assistant Professor of Population Health Sciences Department of Population Health Sciences Duke University School of Medicine

NIH PRAGMATIC TRIALS COLLABORATORY Rethinking Clinical Trials®

Learning goals



- Methods for measuring outcomes using data sources such as electronic health records (EHRs) and patientreported outcomes (PROs)
- Discuss the integration of a health equity lens in evaluating outcomes



Outcome, Measure, Endpoint


- An outcome usually refers to a variable of interest or a meaningful aspect of health (such as oxygen volume or fatigue).
- A measure usually refers to a specific and standardized process to obtain information on an outcome.
 - Includes: instructions, administration materials, content, formatting, and scoring





rules.

NIH PRAGMATIC TRIALS COLLABORATORY Rethinking Clinical Trials*



Outcome, Measure, Endpoint

 An endpoint usually refers to a precisely defined variable that is statistically analyzed to address a particular research question.



Example:

- Change from baseline at 6 weeks in mean PROMIS Fatigue score.
- Mean differences in PROMIS Fatigue scores between patients in treatment and standard of care groups, after controlling for baseline status.


NIH PRAGMATIC TRIALS


NIH PRAGMATIC TRIALS COLLABORATORY


Important things to know 60


- Outcomes and their related endpoints should be meaningful to providers and patients
- Outcomes and related measures should be relatively easy to collect (i.e., pragmatic)
- Researchers do not control the design or data collected in EHR systems












Longitudinal data linkage

- To fully capture all care—complete longitudinal data linking research and insurance claims data is often necessary
- Without explicit consent, getting longitudinal data from an insurance carrier can be an insurmountable hurdle, both technically and legally

NIH PRAGMATIC TRIALS

COLLABORATORY Rethinking Clinical Trials®



Data sources for endpoints in ePCTs

Traditional:

 EHR or ancillary health information systems

Complementary:

Other types of health data not routinely collected outside of standard clinical practice:

- Patient reported data





NIH PRAGMATIC TRIALS

COLLABORATORY Rethinking Clinical Trials®

It's a balancing act

High relevance to real-world decision-making may come at the expense of efficiency




For example, a trial measuring outcomes that matter most to patients and health systems may not be able to rely exclusively on information from the EHR, and instead need to assess patientreported outcomes, which is more expensive and less efficient


Outcomes measured via direct patient report

- PROs are the best way to measure quality of life and often the best way to measure how patients are feeling and functioning.
- Challenges
 - Not routinely or consistently used in clinical care
 - Not regularly recorded in EHR
- Need a mechanism to collect PROs



NIH PRAGMATIC TRIALS






Case example: PPACT

- Project leadership worked with national Kaiser to create buy-in for a common instrument
- Local IT built it within each region
- A multitiered approach supplemented the clinically collected PROM data at 3, 6, 9, and 12 months
- A follow-up phone call by research staff was necessary to maximize data collection at each time point

NIH PRAGMATIC TRIALS COLLABORATORY Rethinking Clinical Trials*



Mobile devices for outcome measurement

- Smartphones, tablet computers, and portable, implantable, or wearable medical devices (mHealth)
 - Some mHealth devices transmit data to a data warehouse every night
 - Largely considered imperfect measures



- "As the number of ePCTs using EHR-derived data grows, so does the risk that research will become more vulnerable to biases due to differences in data capture and access to care for different subsets of the population, thereby propagating inequities in health and the healthcare system"
- Challenges:

Incomplete and variable capture of data on social determinants of health <u>J Am Med Inform Assoc.</u> 2023 Sep; 30(9): 1561–1566. Published online 2023 Jun 26. doi: <u>10.1093/jamia/ocad115</u> PMCID: PMC10436149 PMID: 37364017

NIH PRAGMATIC TRIALS COLLABORATORY Rethinking Clinical Trials®

JVW/


Potential bias and lack of generalizability in electronic health record data: reflections on health equity from the National Institutes of Health Pragmatic Trials Collaboratory

Andrew D Boyd,[⊠] Rosa Gonzalez-Guarda, Katharine Lawrence, <u>Crystal L Patil</u>,

Data loss due to variable use of technology

Lack of representation from vulnerable populations that do not access or receive treatment

NIH PRAGMATIC TRIALS COLLABORATORY Rethinking Clinical Trials®



Data quality assessment

 Identify variation between populations at different sites or study groups

> NIH PRAGMATIC TRIALS COLLABORATORY

- Recommend formal assessment of accuracy, completeness, and consistency for key data
- Data quality should be described, reported, and informed by workflows

Important things to do



- Ask questions that the data will support
- Design trials to minimize new data collection
- Talk to patients and stakeholders when identifying outcomes
- Engage EHR and data experts when defining endpoints
- Budget for data and systems experts at each site (... and then double it)
- Carefully consider bias and take steps to promote equity
- Develop a robust data quality assessment plan to improve value of data and to detect and address data issues – early in data collection

Concluding points

- Data available from the EHR is convenient and pragmatic, but might <u>not</u> actually drive clinical practice or policy if used as endpoints
- Need to make sure that conveniently available endpoints <u>will also be accepted</u> as influential for stakeholders when the ePCT results are disseminated

NIH PRAGMATIC TRIALS COLLABORATORY Rethinking Clinical Trials®

Plan with implementation in mind

